详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

83| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究参与人：

研究单位： [1]Loxo Oncology,Inc. [2]Peking University Third Hospital Beijing,Beijing,China,100191 [3]Xuanwu Hospital Capital Medical University Xicheng District,Beijing,China,100053 [4]Southern Medical University Nanfang Hospital Guangzhou,Guangdong,China,510515 [5]Henan Cancer Hospital Zhengzhou,Henan,China,450008 [6]The Affiliated Hospital of Xuzhou Medical College Xuzhou,Jiangsu,China,221006 [7]The First Affiliated Hospital of Nanchang University Nanchang,Jiangxi,China,330006 [8]The Second Affiliated Hospital of Nanchang University Nanchang,Jiangxi,China,330006 [9]Tianjin Medical University Cancer Institute and Hospital Tianjin,Tianjin,China

研究目的：

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.